montelukast
In       placebo-controlled clinical trials, montelukast significantly improved pulmonary        lung function (as measured by forced expiratory volume in 1 sec), significantly       reduced beta2-agonist use, and significantly improved patient-reported end points       in adults and children (> or =6 y) with chronic asthma.
In       placebo-controlled clinical trials,  @SUBJECT$  significantly  @PREDICAT$   @OBJECT$  (as measured by forced expiratory volume in 1 sec), significantly       reduced beta2-agonist use, and significantly improved patient-reported end points       in adults and children (> or =6 y) with chronic asthma.